Clinical Trial Update: A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974) [Phase 2]

View source ↗

Summary

Phase 2 bridging trial evaluating sugammadex (Org 25969) at 1-2 post-tetanic count in Caucasian participants; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anesthesia-related Conditions

Drugs mentioned

• Sugammadex (sugammadex)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Anesthesia, General | Phase 2 | Status: COMPLETED | Results posted: 2019-02-22